Review

New horizon for infection prevention technology and implantable device

Yusuke Kondo, MD, PhD, Marehiko Ueda, MD, PhD, Yoshio Kobayashi, MD, PhD, Joerg O. Schwab, MD, PhD

1 Department of Cardiology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
2 Department of Cardiology, University of Bonn, Sigmund-Freud Str. 25, 53127 Bonn, Germany

Abstract

There has been a significant increase in the number of patients receiving cardiovascular implantable electronic devices (CIED) over the last two decades. CIED infection represents a serious complication after CIED implantation and is associated with significant morbidity and mortality. Recently, newly advanced technologies have offered attractive and suitable therapeutic alternatives. Notably, the leadless pacemaker and anti-bacterial envelope decrease the potential risk of CIED infection and the resulting mortality, when it does occur. A completely subcutaneous implantable cardioverter defibrillator is also an alternative to the transvenous implantable cardioverter defibrillator (ICD), as it does not require implantation of any transvenous or epicardial leads. Among the patients who require ICD removal and subsequent antibiotics secondary to infection, the wearable cardioverter defibrillator represents an alternative approach to inpatient monitoring for the prevention of sudden cardiac death. In this review paper, we aimed to introduce the advanced technologies and devices for prevention of CIED infection.

Keywords:
Cardiac implantable electronic devices infection (CIED) infection
Wearable cardioverter defibrillator (WCD)
Anti-bacterial envelope
Subcutaneous implantable cardioverter defibrillator (S-ICD)
Leadless pacemaker

Contents

1. Introduction
2. New technologies to reduce the risk of CIED infection
   2.1. Leadless pacemaker
   2.2. Anti-bacterial envelope
3. New technology for prevention of fatal CIED infection
   3.1. Complete subcutaneous implantable cardioverter defibrillator
4. New technology to reduce the risk of sudden cardiac death after the removal of ICD: a wearable cardioverter defibrillator
5. Conclusion

Conflict of interest
References

1. Introduction

There has been a significant increase in the number of patients receiving cardiovascular implantable electronic devices (CIED) over the last two decades [1,2]. This is largely owing to the expanding indications of CIED based on technological improvements and new evidence demonstrating improved survival and quality of life among certain groups of patients having structural heart diseases [3,4]. However, the advantage of these devices is limited by associated adverse events and complications. CIED infection represents a serious complication of cardiac device therapy and is associated with significant morbidity and mortality. Despite appropriate care, in-hospital
Intracardiac pacemaker, has been invented. The concept of a completely self-contained VVIR transvenous electrode lead of the pacemaker, a leadless pacemaker 2.1. Leadless pacemaker

To reduce the complications associated with the standard transvenous electrode lead of the pacemaker, a leadless pacemaker has been invented. The concept of a completely self-contained VVIR intracardiac pacemaker, first explored about 45 years ago by Spickler J et al., has finally become a reality with the development of the Nanostim™ Leadless Pacemaker (St Jude Medical, Inc., St. Paul, MN, USA) and the Micra™ Transcatheter Pacing System (Medtronic plc) for use in humans [13-16]. Technological advances in electronics miniaturization and battery chemistries have enabled creation of a device small enough to be implanted within the heart via a percutaneous, transvenous approach, while still providing similar battery longevity without leads. The leadless pacemaker has been expected to reduce CIED infections, because this system has no physical connection between the endocardium and the subcutaneous pocket, which are the most likely source and channel of bacterial infection, respectively. Furthermore the leadless stand-alone system never produces subclavian or supra vena-cava occlusions. Both systems have received the CE Mark in Europe, but are not approved in the USA.

The Nanostim system is delivered to the implant site at the lower septum of the right ventricle (RV) via a transfemoral route and allows for bradycardia pacing via a miniature pulse generator with a built-in battery and electrodes that can be entirely and permanently implanted (Fig. 2). The first successful Nanostim implantation in humans took place in December 2012 in Prague, Czech Republic. Recently, a nonrandomized first-in-human study

![Image](https://example.com/image1)

Fig. 1. A case of cardiac implantable electronic device infection.

The majority of patients with CIED infection have pocket and/or endovascular lesions (Fig. 1). If aggressive antibiotic therapy fails to control CIED infection, then complete removal of the device is recommended in many instances [2,6]. The timing of re-implantation is another critical issue. An early re-implantation should be performed in patients who are solely dependent on the CIED; however, at least one week is required to control local or systemic bacterial infections [12]. Currently, the advanced technologies may contribute to a decrease in infection risk and mortality and may bridge the critical period between device removal and re-implantation.

2. New technologies to reduce the risk of CIED infection

In the USA and Europe, some new alternatives to prevent CIED infection are available. The leadless pacemaker and antibacterial envelope represent attractive and suitable therapeutic options to minimize the risk of CIED infection.

2.1. Leadless pacemaker

![Image](https://example.com/image2)

Fig. 2. The Nanostim™ Leadless Pacemaker (St Jude Medical, Inc., St. Paul, MN, USA) Reprinted with permission from St Jude Medical, Inc.

The Nanostim pacemaker communicates with the St. Jude Medical Merlin™ Patient Care System using a programmer link and surface electrocardiographic electrodes, and (iv) the Micra device demonstrated this system to be safe and feasible over a 90-day period [15]. This preclinical study expanded on the previous study by demonstrating that the pacing and sensing properties remain adequate for up to 18 months. In addition, the histological analyses at the 90-day mark revealed a limited local response to the implanted device at the RV apex. Furthermore, there were no significant adhesions between the device and the RV walls. These pathological features may have important implications related to the long-term efficacy and safety of this system, as well as for designing approaches to extract the device.

The Micra system, similar to the Nanostim system, is an investigational device and is being assessed in a pivotal global clinical trial. The miniaturized device is only one-tenth the size of a conventional pacemaker (Fig. 3). The Micra system is also delivered directly into the heart through a catheter inserted in the femoral vein. Once positioned, the pacemaker is securely attached to the heart wall in the RV and can be repositioned or retrieved during implantation if needed (Fig. 4). The device does not require the use of leads and is attached via small tines securing it to the heart wall. The first successful in-human Micra implantation occurred in December 2013 in Linz, Austria. It is currently being evaluated in the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial, which is a single-arm, multicenter study that will enroll up to 780 patients at approximately 50 centers [16].

Both systems allow for retrievability, if needed; however, there are significant differences in the designs that are worth noting: (i) the Micra device has an active fixation mechanism consisting of four electrically-inactive extendable and retractable tines to anchor it to the cardiac tissue, whereas the Nanostim device uses an electrically active fixed helix, (ii) the Micra device is wider (20 Fr) and shorter (25.9 mm) than the Nanostim pacemaker (18 Fr and 41.4 mm), (iii) the Micra pacemaker’s communication between the device and programmer is established using a standard programming head, whereas the Nanostim pacemaker communicates with the St. Jude Medical Merlin™ Patient Care System using a programmer link and surface electrocardiographic electrodes, and (iv) the Micra device

![Image](https://example.com/image3)

Fig. 3. The Micra™ Transcatheter Pacing System (Medtronic plc). Reprinted with permission from Medtronic plc.

...
uses a three-axis accelerometer for rate response, whereas the Nanostim pacemaker utilizes a blood temperature sensor. The most relevant limitation is that the current Nanostim and Micra devices are indicated for patients requiring a single-chamber pacemaker only, limiting their use to a relatively small percentage of patients. Current indications focus on patients with chronic atrial fibrillation and second- or third-degree atrioventricular block, patients with sinus rhythm with second- or third-degree atrioventricular block and a low level of physical activity or short expected lifespan, and patients with sinus bradycardia with infrequent pauses or unexplained syncop.

2.2. Anti-bacterial envelope

Previously published randomized controlled studies indicate that perioperative intravenous administration of a cephalosporin antibiotic can help to reduce CIED infections [2,18]. The European Society of Cardiology, American Heart Association, and Heart Rhythm Society recommendations for prophylaxis at the time of CIED placement consist of an antibiotic that has in-vitro activity against staphylocci. In recent large studies, the vast majority of patients received antimicrobial prophylaxis with CIED placement [19,20]. Despite widespread use of antimicrobial prophylaxis, CIED infection rates are increasing faster than implantation rates [21]. Effective antimicrobial prophylaxis could help reduce CIED infections and improve clinical outcomes.

The TYRX™ Antibacterial Envelope (Medtronic plc) consists of a Food and Drug Administration (FDA)-approved surgical mesh envelope that releases minocycline and rifampin in the generator pocket after implantation with a CIED (Fig. 5) [17]. The biocompatible mesh is coated with antibiotics that elute (dissolve) within an approximately 7-day period. The TYRX™ is of two types, with substrate meshes that are 100% absorbable or non-absorbable. A recent report suggests that the use of the TYRX™ absorbable envelope was associated with a very low prevalence (0%) of CIED-related infections that was comparable to that seen with the non-absorbable envelope. However, data from a randomized clinical trial are needed to support increased use of the antibacterial envelope [22]. Both TYRX™ Antibacterial Envelopes are sterile devices constructed of an open-pore weave, knitted filaments of a lightweight mesh, and an absorbable polymer coating impregnated with antimicrobial agents. The antibacterial envelope is indicated for holding CIEDs, thereby creating a stable environment surrounding the device and leads after surgical placement.

At least one-half to two-thirds of CIED infections are caused by Staphylococcus aureus (S. aureus) and coagulase-negative staphylococcus species (CoNS) [18,20,23–25]. In vitro, methicillin-resistant strains of S. aureus and many strains of CoNS are susceptible to a combination of two antibiotics with distinct mechanisms of actions: minocycline and rifampicin [26–28]. Rifampicin is bacteriostatic and inhibits DNA-dependent RNA polymerase. Minocycline is bacteriostatic and inhibits protein synthesis. Minocycline has an antimicrobial spectrum against a wide range of gram-positive and gram-negative organisms. Rifampin is a semi-synthetic compound derived from Amycolatopsis rifamycinica and has antimicrobial activity against select gram-positive and gram-negative organisms. The substrate mesh varies between the two types of envelopes and consists of either polypropylene or Glycoprene II. Polypropylene has been utilized in surgically implanted medical devices for decades. The most common use is in hernia repairs.

The absorbable tyrosine-based polymer coating is designed to degrade to well-characterized natural metabolites. It has been demonstrated to resorb benignly, in the same manner as absorbable surgical sutures, while eliciting a minimal inflammatory response. It also has a long history of use with other FDA-approved implantable medical devices. Randomized controlled trials demonstrated that coating or impregnating catheters with the combination of rifampin and minocycline significantly reduces device-associated infections of central venous, hemodialysis, and cerebrospinal fluid drain catheters, especially infections with S. aureus and CoNS [29–35]. Preclinical studies demonstrated that the antibacterial envelope helped reduce the risk for infection by several pathogens, including Staphylococcus epidermidis, within CIED implant pockets [36]. A previous large clinical study indicated that the envelope is associated with a high rate of successful CIED implantation and a low risk of infection in a population at significant risk for CIED infection. Furthermore, standard use of an antibacterial envelope was associated with a significantly lower rate of CIED infection and appeared to be economically viable [37].

3. New technology for prevention of fatal CIED infection

It is widely accepted that complication rates are higher with re-implantations, particularly if a lead implantation or revision is involved [38,39]. In addition, morbidity and mortality is particularly high in patients with an infected transvenous implantable
cardioverter defibrillator (transvenous-ICD) system, especially when a systemic infection or endocarditis is present.

The risk of reinfection following system re-implantation is also a concern [40,41].

A completely subcutaneous ICD was developed as an alternative to the transvenous-ICD system, as it is implanted without any transvenous or epicardial leads. The rate of infections resulting in explantation or revision of this new device was not lower than that reported in previous ICD registries. However, it should be emphasized that none of the documented device infections were systemic [42].

3.1. Complete subcutaneous implantable cardioverter defibrillator

The completely subcutaneous ICD system (S-ICD™ System, Boston Scientific Corp., Marlborough, MA, USA) was developed to provide life-saving defibrillation therapy while leaving the heart and vasculature untouched [43]. The S-ICD system is preferred over transvenous-ICD for patients having no vascular access, a history of recurrent transvenous lead infections, or primary electrical disease with ventricular fibrillation as the major life-threatening rhythm. The first pilot-phase human studies of the S-ICD commenced in 2008, followed by subsequent regulatory and post-marketing studies. Approved by the FDA in September 2012, to provide defibrillation therapy for the treatment of ventricular tachyarrhythmias, the S-ICD system was developed after 10 years of defibrillation and sensing research, acute human feasibility studies, and long-term clinical studies [43–49]. This system demonstrated a very high shock efficacy for spontaneous ventricular arrhythmias and a decreased incidence of inappropriate shocks [48].

The S-ICD system is comprised of a pulse generator, subcutaneous electrode, electrode-insertion tool, and device programmer. The pulse generator has an estimated longevity of 5 years and is slightly larger with a weight (145 g) approximately double that of a modern transvenous ICD generator [49]. It provides high-energy defibrillation shock (80 J) therapy through the use of a constant-tilt biphasic form. In addition, the new generation S-ICD System (EMBLEM™ [Fig. 6]), which is 20% thinner and is projected to last 40% longer than the previous S-ICD system, is available in a small number of centers in Europe and USA. This system is also enabled for remote patient management for increased patient convenience. The generator is placed subcutaneously in a left lateral position over the 6th rib between the midaxillary and anterior axillary lines. Via two parasternal incisions, a 3 mm tripolar parasternal electrode (polycarbonate urethane) is positioned parallel to and 1 to 2 cm to the left of the sternal midline with the distal sensing electrode localized adjacent to the manubriosternal junction and the proximal sensing electrode positioned adjacent to the xiphoid process (Fig. 7).

A population-based decrease in mortality with a new device is paramount, but can be negated if the implant is associated with a higher risk of removal due to pocket infection. Infection without any bacteremia remained the most common complication requiring invasive action in the early experience with the S-ICD [44–46]. Many steps were taken to mitigate this risk and prevent device removal, including better operative preparation training and techniques and aggressive management of skin infections [45]. Advances in implantation techniques were introduced in the literature by Knops et al. in an effort to reduce the incisional surface area and resulting infection risk [50]. Advances in operator experience, preparation, and implantation techniques appear to have positively affected the rates of infection, as use of the S-ICD system has expanded worldwide. In recent studies, the simplicity of implantation which avoids vascular access was reflected in the very low rate (2%) of acute major complications such as device system infection [48]. The S-ICD could be a new alternative to the conventional transvenous-ICD system to minimize device system infections.

The limitations of the current S-ICD include its inability to provide anti-tachycardia pacing for ventricular tachycardia, limited bradycardia pacing support, and absence of endovascular monitoring capabilities for collateral data gathering such as impedance monitoring for chronic heart failure. One estimate of potential candidates for the S-ICD includes every patient indicated for primary SCD prevention without a pacemaker indication. In addition, the use of a subcutaneous sensing electrode with the S-ICD may theoretically increase the risk of over-sensing noise or myopotential signals and under-sensing low-amplitude cardiac signals during ventricular fibrillation. The previous trial compared the arrhythmia detection of 3 commercially available transvenous ICD lead systems with the S-ICD electrode [51]. All devices excelled in detecting ventricular tachyarrhythmia (100%); however, the S-ICD demonstrated greater specificity in discriminating supraventricular from ventricular tachycardia (98% S-ICD vs. 76.7% single-chamber transvenous-ICD vs. 68.8% dual-chamber transvenous-ICD). Ideally, greater user programming experience and improvements in S-ICD technology may reduce the rate of inappropriate shocks.

4. New technology to reduce the risk of sudden cardiac death after the removal of ICD: a wearable cardioverter defibrillator

ICD therapy has been established as a cornerstone of cardiology practice for reducing the incidence of SCD [52–55]. Unfortunately, ICD system infection represents a complication that occurs even in experienced centers. Among patients who require ICD removal and subsequent antibiotic therapy, a wearable cardioverter defibrillator (WCD; LifeVest WCD4000, ZOLL, Pittsburgh, PA, USA) represents an alternative approach to prevention of SCD. Removal of the ICD deprives the patient of the protection against potential life-threatening ventricular tachyarrhythmias, particularly in patients with ICD implantation for secondary prevention of SCD. The Heart
morbidity and mortality. However, newly developed technologies and devices represent attractive and suitable therapeutic options to reduce the incidence of this increasing problem.

**Conflict of interest**

Dr. Kondo has received a research grant from St. Jude Medical, Biotronik. Dr. Ueda has received an unrestricted educational donation from St. Jude Medical. Dr. Kobayashi has received a research grant from Medtronic, St. Jude Medical, Boston Scientific, and Biotronik. Dr. Schweb has received speaking honoraria and research support from Medtronic, Biotronik, St. Jude Medical, Boston Scientific, and Sorin.

**References**

[1] Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. J Am Med Assoc 2006;295:809–18.

[2] Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458–77.

[3] Hayes DI, Furman S. Cardiac pacing: how it started, where we are, where we are going. Pacing Clin Electrophysiol 2004;27:693–704.

[4] Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:51–62.

[5] Kolek MJ, Dresen WF, Well QS, et al. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol 2013;36:354–61.

[6] Tarikici KC, Chan EI, Cantillon DJ, et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm 2010;7:1043–7.

[7] Uslan DZ, Sohall SR, Sauer JL, et al. Permanent pacemaker and implantable cardioverter-defibrillator infection: a population-based study. Arch Intern Med 2007;167:669–75.

[8] Baman TS, Gupta SK, Valle JA, et al. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol 2008;2:129–34.

[9] Athan A, Chui VH, Tatsnev P, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. J Am Med Assoc 2012;307:1727–35.

[10] Le KY, Sohall MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011;8:1678–85.

[11] Dehoro JC, Quatre A, Mancini JJ, et al. Long-term outcomes following infection of cardiac implantable electronic devices: a prospective matched cohort study. Heart 2012;98:724–31.

[12] Healy CA, Carrillo RG. Wearable cardioverter defibrillator for prevention of sudden cardiac death following infected implantable cardioverter defibrillator removal: a cost-effectiveness evaluation. Heart Rhythm 2015;12:1965–73.

[13] Spickler JW, Rasor NS, Kezdi P, et al. Totally self-contained intracardiac pacemaker. J Electrocardiol 1970;3:325–31.

[14] Koruth S, Rippy MK, Kharkhara A, et al. Feasibility and efficacy of percutaneously delivered leadless cardiac pacing in an in vivo ovine model. J Cardiovasc Electrophysiol 2015;26:322–8.

[15] Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation 2014;129:1466–71.

[16] Ritter P, Duray GZ, Zhang S, et al. The rationale and design of the Micra Transcatheter Pacing System: safety and efficacy of a novel miniaturized pacemaker, Europe 2015;17:807–13.

[17] Shariff N, Eby E, Adamstein E, et al. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device infections. J Cardiovasc Electrophysiol 2015;26:783–9.

[18] de Oliveira JC, Martinelli M, Nishikawa SADO, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:29–34.

[19] Gould PA, Gula LJ, Champagne J, et al. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm 2008;5:1675–81.

[20] Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007;116:1349–55.

[21] Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol 2010;33:414–0.

[22] Kolek MJ, Patel NJ, Clair WK, et al. Efficacy of a bio-absorbable antibacterial envelope to prevent cardiac implantable electronic device infections in high-risk subjects. J Cardiovasc Electrophysiol 2015;26:1111–6.
